bluuebunny/crossref_metadata_2025_split huggingface dataset:
Simultaneous intracoronary testing for endothelial dysfunction and coronary vasospasm in patient with angina and non-obstructive coronary artery disease
Authors: Feenstra R G T , Boerhout C K M , Woudstra J , Vink C E M , De Waard G A , Appelman Y , Eringa E C , Marques K M J , De Winter R J , Van De Hoef T P , Beijk M A M , Piek J J 
Published: October 2021

Abstract

Introduction
Currently, two different theories exist on testing for coronary functional disorders in patients with angina and no obstructive coronary artery disease (ANOCA) where either invasive testing for endothelial function or coronary spasm provocation is performed. In this study we aim to assess the concomitant occurrence of both conditions in a cohort of patients with ANOCA undergoing both endothelial function testing and spasm provocation.

Methods
In this retrospective study, we included 114 patients that have undergone invasive coronary vasomotor function testing for coronary endothelial function and coronary artery spasm provocation. Endothelial dysfunction was defined as a &lt;50% increase in coronary blood flow and/or epicardial coronary diameter reduction compared to baseline in reaction coronary acetylcholine concentrations up to 10–6 mol/L. Coronary artery spasm (CAS), defined as VSA and/or MVA due to microvascular spasm, was defined according to the COVADIS criteria in reaction to coronary acetylcholine concentration up to 10–5 mol/L.

Results
Among the 114 patients, 90 (78%) could be diagnosed with endothelial dysfunction and 71 (62%) with CAS. In most patients, 60 (54%), endothelial dysfunction and CAS can be diagnosed concurrently, whereas only 30 had endothelial dysfunction without CAS and 11 patients had CAS with a normal endothelial function.

Conclusion
In this cohort of ANOCA patients undergoing testing for coronary endothelial function and spasm provocation a large overlap of concurrent endothelial dysfunction and spasm provocation was found. These findings suggest a role for simultaneous endothelial function testing and spasm provocation in coronary vasomotor function protocols in order to adequately identify endotypes of ANOCA.

Funding Acknowledgement
Type of funding sources: None.
LGE-cMRI assessment of volume controlled reperfusion method in primary percutaneous coronary intervention in patients with ST elevated myocardial infarction
Authors: He J , Yang X C , Wang L F ,   VCR
Published: October 2021

Abstract

Objectives
We create a procedure based on postconditioning and gradual reperfusion, “Volume Controlled Reperfusion Revascularization” method (VCR)in primary percutaneous coronary intervention. The aim of this experimental study is to assess feasibility and effect of VCR and if this method will attenuate reperfusion injury in microvascular obstruction.

Methods
VCR method, Basically, contemporaneous forward blood flow balloon inflation blocking at the occlusion site and prolonged distal reperfusion via aspiration catheter. Active NC balloon inflation at occlusion site, while keeping NC balloon inflation, aspiration catheter was positioned 10–15mm advanced of NC balloon, intra-aspiration catheter infusion of mixture solution (artery blood 10ml+ heparin NS 10ml), 20ml/min for 10mins, adjust volume and speed according to blood pressure and heart rate variation. Stent or DCB as usual. After several successful operation on RCA, 10 patients with acute ST-segment elevation myocardial infarction (STEMI)with angiography confirmed proximal complete occlusion on dominant blood vessel were non-randomly enrolled (symptom to angiography &lt;12h). 5 cases in VCR group with volume-controlled reperfusion revascularization method, 5 cases in control group with conventional PCI method. Microvascular obstruction (MVO) has been calculated by late gadolinium-enhanced cardiovascular magnetic resonance (LGE-cMRI). Base line information, angiographic features before and after procedure, in-hospital status and MVO were compared.

Results
Successful PCI procedure, safe in-hospital treatment and LGE-cMRI assessment for MVO. Group difference were found in age group and PCI to MRI interval (53.8±7.6 vs 70.2±4.44, P=0.0031; 7.4±2.3 vs 10.4±1.67, P=0.046) between VCR and control group, respectively. There was no statistic difference in other base line information, peak myocardial enzyme, and BNP. MVO and MVO mass ratio was significantly lower in VCR group (0.78±0.96 vs 2.80±1.37, P=0.0317; 0.00585±0.00080 vs 0.02493±0.01501, P=0.0372). TIMI III blood flow found in VCR group. Re-myocardial infraction nor target vessel revascularization was documented in-hospital or 30-days follow up.

Conclusion
Among the selected small sample cases, volume-controlled reperfusion method procedure was clinical safe and feasible without additional side effect. TIMI III blood flow and less MVO were documented.

Funding Acknowledgement
Type of funding sources: None. LGE-cMRI results in VCR and controlCase illustration of VCR procedure
Outcomes after percutaneous coronary intervention (PCI) in patients with prior coronary artery bypass grafting (cabg)
Authors: Cohen N S , Dinh D , Ajani A , Clark D , Brennan A , Nan Tie E , Dagan M , Hamilton G , Sebastian M , Shaw J , Oqueli E , Freeman M , Reid C , Stub D , Duffy S J 
Published: October 2021

Abstract

Background
In patients with prior CABG requiring subsequent PCI there is uncertainty whether bypass grafts or native coronary arteries should be targeted.

Methods
We analysed data from 2,764 patients with prior CABG in the Melbourne Interventional Group registry (2005–2018), divided into two groups: those undergoing PCI to a native vessel (n=1,928) and those with PCI to a graft vessel (n=836).

Results
Patients with a graft vessel PCI were older, had more high-risk clinical characteristics (prior MI, heart failure, ejection fraction &lt;50%, renal impairment, peripheral and cerebrovascular disease), and high-risk procedural features (ACC/AHA types B2/C lesions). However, patients in the native vessel group were more likely to have PCI to a chronic total occlusion. The majority of graft PCI were to saphenous vein grafts (84%), with 10% to radial and 6% to LIMA/RIMA grafts. Distal embolic protection devices were used in 30% of graft PCI. Patients with graft PCI had higher rates of no reflow (6.3% vs. 1.5%; p&lt;0.001), coronary perforation (p=0.016) and inpatient stent thrombosis (p=0.028). However, 30-day mortality and major adverse cardiovascular and cerebrovascular events (MACCE) were similar. Unadjusted long-term mortality (median follow up 4.8 years) was higher in patients who had undergone a graft PCI (44% vs. 32%, p&lt;0.001), but following Cox proportional hazards modelling, PCI vessel type was not a predictor of long-term mortality (HR 1.13; 95% CI 0.96–1.33, p=0.14).

Conclusions
Early clinical outcomes and risk-adjusted long-term mortality are similar for patients with prior CABG undergoing PCI to a native vessel or a bypass graft.

Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): The Alfred Hospital
Impact of COVID-19 lockdowns on STEMI percutaneous interventions
Authors: Zlochiver V , Perez Moreno A C , Hall J , Hommeida M , Allaqaband S Q , Bajwa T , Jan M F 
Published: October 2021

Abstract

Background
Measures taken to mitigate the spread of coronavirus disease 2019 (COVID-19) have been correlated to a decline in the number of patients seeking medical care for emergency cardiovascular illness. Here we evaluate the impact of a state-wide lockdown on ST-elevation myocardial infarction (STEMI) care.

Purpose
The purpose of this study is to help understand the impact of COVID-related lockdowns on STEMI interventions.

Methods
All consecutive adult patients admitted with an acute STEMI diagnosis and percutaneous intervention (PCI) performed between January 17, 2020, and July 14, 2020, at five sites across our health care network, were included in this study. Patient demographics, medical history and procedure details were collected retrospectively from electronic medical records. Data were segregated according to date into pre-lockdown, lockdown (March 17 to May 13, 2020) and post-lockdown groups.

Results
A total of 225 patients formed the study cohort. Median age was 62 (IQR: 53–71) years. Patients were predominantly male (n=154, 68%), white (n=208, 92%), hypertensive (n=139, 61%) and dyslipidemic (n=135, 60%). The average weekly rate of STEMI PCIs performed pre-lockdown decreased by 40% during the lockdown from 10.9 to 6.5 PCIs per week (p&lt;0.05). Door-to-balloon (D2B) times increased from 42 (IQR: 28–68) min pre-lockdown to 53 (IQR: 40–72) min during the lockdown (p=0.01). No significant differences were observed in in-hospital mortality or cardiac troponin measurements within 24 h of procedure between the three groups.

Conclusion
Adverse effects of COVID-19-related lockdowns on acute STEMI care include a decrease in PCI volumes and prolonged D2B times. Our results provide valuable data-driven criteria to help inform patient decisions to seek care and to find ways to protect healthcare workers without compromising timely critical intervention.

Funding Acknowledgement
Type of funding sources: None.
Comparative analysis of sequential pot-side-pot and kissing balloon techniques in patients with coronary bifurcation lesions treated with single stent strategy: propensity score analysis
Authors: Cetinkal G , Balaban Kocas B , Keskin K , Kilci H , Ser O , Yildiz S S , Sigirci S , Gurdal A , Sumerkan M C , Kilickesmez K 
Published: October 2021

Abstract

Objectives
It is unknown whether the novel re-POT technique is more effective than commonly preferred kissing balloon inflation (KBI) in patients with non-complex coronary bifurcation lesions (CBL) treated with single-stent strategy. Our aim was to compare the efficacy of re-POT and KBI techniques in one-stent strategy of non-complex CBL.

Methods
283 patients were retrospectively analyzed (re-POT group, n=149; KBI group, n=134). Primary end-points of the study were defined as; in-hospital and 30-day mortality, contrast induced acute kidney injury (CI-AKI), stent thrombosis (ST), side branch (SB) dissection and need for SB stenting. Characteristics of patients at baseline were balanced by using propensity score inverse probability weighting (IPW).

Results
Procedure time (minute, 30.6±8.5 vs 34.3±11.6; p=0.003) and contrast volume (mL, 153.7±42.4 vs 171.1±58.2; p=0.004) were significantly lower in re-POT group. Besides, SB residual stenosis and number of patients with &gt;50% SB residual stenosis remained significantly higher in re-POT group both in general and true bifurcation subgroup analysis (20.3±19.8% vs 16.5±16.4%, p=0.02; 11.9% vs 5.7%, p=0.01 and 24.1±23.2% vs 18.8±18.7%, p=0.03; 17.6% vs 6.6%, p=0.005; respectively). Combined clinical adverse outcomes were similar between groups. (Figure 1) SB dissection (10.2% vs 20.1%, p=0.001) and need for SB stenting (12.6% vs 19%, p=0.04) were reached statistically significance in KBI group after adjustment. (Figure 2)

Conclusions
Re-POT may be a simple and safe technique with a shorter procedure time and lower incidence of adverse events in non-complex CBL treated with single-stent strategy.

Funding Acknowledgement
Type of funding sources: None. Adverse clinical outcomes; weighted
Use of sirolimus-coated balloon in de novo lesions; Mid-term follow-up from a single-centre registry
Authors: Loku Waduge B H , Kalkat H , Saif A , Fawzy A M , Athulorala S , Bhatia G , Kumar N , Freestone B , Ment J , Lee K , Pitt M , Pulikal G , Basavarajaiah S 
Published: October 2021

Abstract

Introduction
Use of drug coated balloons (DCBs) in coronary intervention is escalating and the guidelines recommend its use in restenotic lesions. However, recent data suggest it can also be considered in a subset of denovo lesions especially; small vessels, ostium of an important side-branch and in patients unable to tolerate dual antiplatelet therapy for a prolonged period. Most DCBs used elute Paclitaxcel, but there is no data on Sirolimus eluting DCB, which is the drug of choice in currently available drug eluting stents. In this study, we report outcomes from the use of a Sirolimus coated balloon (SCB) in de novo coronary lesions.

Methods
We retrospectively analysed all patients treated with an SCB between April and December 2018. Results are reported as cardiac death, target vessel myocardial infarction (TVMI), target lesion revascularisation (TLR), target vessel revascularisation (TVR) and MACE (combination of cardiac death, target vessel MI and TLR).

Results
During the study period, 351 patients (with 414 lesions) with de novo lesions were treated with an SCB. The mean age of patients was 65.6±11.5 years, 275 (78%) were male and 39% (n=212) had diabetes. Most lesions treated were in the LAD/diagonal system (n=173, 42%). Predilatation was performed in 98% (405 lesions). Bailout stenting (with a drug eluting stent) was required in 7% lesions (n=30), of which 11 were due to dissections and 19 were due to recoil &gt;50% following DCB use. The mean diameter and length of DCBs were 2.47 mm and 26 mm respectively.
During a median follow-up of 322-days (11-months) cardiac death was reported in 8 patients (2.3%). Target vessel MI was in 3%; n=10, TLR and TVR per lesion were 8% (n=34) and 9% (n=37) respectively. The MACE rate was 11%. There were no documented cases of acute vessel closure.

Conclusion
The mid-term outcome from the first ever study on sirolimus coated balloons in de novo lesions appears promising with low rates of hard endpoints with no documented cases of acute vessel closure. The MACE rates appear promising, although we need longer follow-up which is ongoing and we will be able to report outcomes from even longer follow-up during the presentation.

Funding Acknowledgement
Type of funding sources: None.
Urgent vs non-urgent transcatheter aortic valve implantation outcomes
Authors: Castelo A , Grazina A , Mendonca T , Rodrigues I , Garcia Bras P , Vaz Ferreira V , Ramos R , Fiarresga A , Cacela D , Cruz Ferreira R 
Published: October 2021

Abstract

Background
There are limited data about the outcomes of non-elective transcatheter aortic valve implantation (TAVI), but some studies suggest that these patients have worst results.

Purpose
To compare outcomes in patients submitted to urgent versus elective TAVI.

Methods
Retrospective analysis of consecutive patients (P) submitted to TAVI between 2018 and 2020 in a tertiary center. Baseline characteristics and outcomes after the procedure were collected. Urgent TAVIwas considered when patients were not electively admitted for the procedure but required the intervention on the current admission for medical reasons and could not be sent home without a definitive procedure.

Results
A total of 208P (55,3% female) were included, with a mean age of 82±7 years. Patients submitted to urgent TAVI (57P, 27,4%) had worse baseline characteristics, with higher EuroScore risk (10,7% vs 5,4%, p&lt;0,001), STS score (7,3% vs 4,4%, p&lt;0,001), and natriuretic peptide B (1350 vs 728 pg/mL, p=0,021), lower left ventricle ejection fraction (44% vs 50%, p&lt;0,001), more diabetes (49,1% vs 33,1%, p=0,033), peripheral artery disease (22,8% vs 4,6%, p&lt;0,001) and worse accesses (21,2% vs 5%, p=0,002). In univariable analysis, urgent TAVI was associated with higher intra-hospital mortality (14% vs 4%, p=0,01), 30-days mortality (17,5% vs 4%, p=0,001) and 30-days cardiovascular mortality (17,5% vs 3,3%, p&lt;0,001), life- threatening bleeding (17,9% vs 4%, p=0,001), acute kidney injury (16,1% vs 4,7%, p=0,007), vascular complications (16,1 vs 4%, p=0,003) and longer hospital and intensive care unit stay (30 vs 12 days, p&lt;0,001 and 6 vs 4 days, p=0,025 respectively), but not with post-TAVI hospital stay (12 vs 10 days, p=0,37). When adjusted to the differences in baseline characteristics, in a multivariable analysis, urgent TAVI was only associated with longer hospital stay (p&lt;0,0001). There were no differences in outcomes between groups beyond the first 30 days after the procedure, including mortality and hospital admissions.

Conclusion
Patients submitted to urgent TAVI tend to have worse short-term outcomes, but this seems to be attributable to the worse baseline characteristics of these cases instead of the urgent nature of the procedure. Even with the adjustment for baseline differences, these patients have longer global hospital stays, but they don't have latter post-TAVI discharge.

Funding Acknowledgement
Type of funding sources: None.
Periprocedural and short-term stroke after transcatheter aortic valve implantation – what are the outcomes and how can we predict it
Authors: Castelo A , Grazina A , Mendonca T , Rodrigues I , Vaz Ferreira V , Garcia Bras P , Ramos R , Fiarresga A , Cacela D , Cruz Ferreira R 
Published: October 2021

Abstract

Background
Stroke is a known complication after transcatheter aortic valve implantation (TAVI). Although risk factors for its occurrence are being suggested, we still don't have clear tools to predict which patients will most probably have it and how to prevent it.

Purpose
To identify possible clinical and procedural predictors of early post-TAVI stroke.

Methods
Retrospective analysis of consecutive patients (P) submitted to TAVI between 2009 and 2020 in a tertiary center. Baseline characteristics, procedural information and stroke in first 30 days after TAVIwere collected.

Results
A total of 494P (56,1% female) were included, with a mean age of 82±6 years (minimum 45 and maximum 95 years- old). The majority (98,4%) had at least one cardiovascular risk factor (83,2% hypertension, 67,6% dyslipidemia, 64% excess weight, 36,8% diabetes, 11,9% smoking). Half patients had chronic kidney disease, 34,8% atrial fibrillation, 16,4% peripheral artery disease, 15,4% porcelain aorta, and 12,3% a previous stroke. The procedure was done via transfemoral access in 460P (93,1%), subclavian artery in 16P (3,2%), transcava in 10P (2%) and transaortic in 7P (1,4%). Aortic valve pre-dilation was done in 35,6% and post-dilation in 31,2%. In the first 30 days after TAVI 19P (3,8%) had a stroke (11P with a major and 8P with a minor stroke). Patients with stroke had more hypertension (100% vs 82,4%, p=0.045), higher BMI (29 vs 27, p=0.039) and more frequently porcelain aorta (36,8% vs 15,5%, p=0,014). They also tended to have more peripheral artery disease (31,6% vs 15,7%, p=0,066). There weren't other differences in baseline characteristics between the two groups. Considering the aspects related to the procedure, post-dilation was the only predictor of events (58,8% vs 32%, p=0,021). In a multivariable analysis including clinical and procedural predictors, porcelain aorta (p=0,048, OR = 2,895) and post-dilation (p=0,042, OR = 2,844) were the independent predictors. Stroke after TAVI was associated with longer hospital stay (36 vs 15days, p&lt;0,001) and intensive care unit stay (12 vs 3 days, p&lt;0,001), higher intra-hospital mortality (14,8% vs 3,2%, p=0,002), global 30-day mortality (12,1% vs 3,3%, p=0,0011) and cardiovascular 30-day mortality (11,5% vs 3,4%, p=0,038).

Conclusion
Periprocedural and 30-day stroke is a relatively uncommon but potentially devastating complication after TAVI. There are clinical and procedural characteristics that are associated with a higher risk and should be considered when selecting patients for treatment and strategies to prevent events.

Funding Acknowledgement
Type of funding sources: None.
Effects of a diuretic regimen on body weight and echocardiographic parameters of the tricuspid valve in patients scheduled for transcatheter tricuspid annuloplasty
Authors: Landendinger M , Haug J , Achenbach S , Arnold M B 
Published: October 2021

Abstract

Background
Echocardiographic severity of tricuspid regurgitation is known to be highly variable and strongly related to the volume status of the individual patient. Interventional therapies for tricuspid valve repair or replacement are dependent on reliable measurements in order to select the appropriate device size.

Purpose
In patients scheduled for transcatheter tricuspid valve annuloplasty, we sought to evaluate the effects of a diuretic regimen started at the screening visit on body weight and tricuspid valve dimensions at the time point of transcatheter intervention.

Methods
After successful screening for transcatheter tricuspid annuloplasty, an individualized intensified diuretic regimen was initiated in 15 patients. At baseline and at the timepoint of the intervention, body weight and 3D echocardiographic dimensions of the tricuspid valve were documented and compared.

Results
The cohort comprised 6 males and 9 females (mean age 77±7 years) with severe or higher degree functional tricuspid regurgitation. In all patients not more than mild pulmonary artery hypertension was present (PaP mean 29±5 mmHg). The interval between the screening visit and the timepoint of the procedure was 64±50 days. At baseline mean body weight was 72±12 kg. In 11 patients a reduction of the body weight could be achieved, with a median weight reduction of 2.2 kg (min/max 1.2/6.4 kg). Overall, the average relative reduction of the tricuspid annulur perimeter was 13% (p&lt;0,001), of the tricuspid valve area 2.7% (n.s.), the anterseptal diameter 3.3% (n.s.), while the bicommissural diameter remained almost unchanged (0.4%; n.s.). The average predicted required band length changed by only 1.5% (n.s.). The strongest correlations were found between the absolute change in body weight and the change of the tricuspid valve area (r=0.48), relative change in body weight and relative change of tricuspid valve area (r=0.52), absolute change in body weight and absolute change in predicted band length (r=0.48), and relative changes of the respective variables (r=0.52). More importantly, in 13 out of 15 patients the band size which would have been selected was identical between the screening and the annuloplasty procedure. Only in two patients a smaller device was implanted than predicted at the screening visit.

Conclusion
Instituting a diuretic therapy in candidates for transcatheter tricuspid annuloplasty prior to the procedure helps to keep tricuspid valve dimensions in a stable range. Changes in body weight in patients with functional tricuspid regurgitation are correlated to changes of tricuspid valve dimensions.

Funding Acknowledgement
Type of funding sources: None.